Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Join | Sign in
Home>Videos>This Video
  Videos

Return

Tumour Regression after Intravenous Administration of Novel Tumour-targeted Nanomedicines
SELECTBIO

The possibility of using genes as medicines to treat cancer is limited by the lack of safe and efficacious delivery systems able to deliver therapeutic genes selectively to tumours by intravenous administration, without secondary effects to healthy tissues. In order to remediate to this problem, we investigated if the conjugation of the polypropylenimine dendrimer to transferrin, whose receptors are overexpressed on numerous cancers, could result in a selective gene delivery to tumours after intravenous administration, leading to an increased therapeutic efficacy. The objectives of this study are to evaluate the targeting and therapeutic efficacies of a novel transferrin-bearing polypropylenimine dendrimer. The intravenous administration of transferrin-bearing polypropylenimine polyplex resulted in gene expression mainly in the tumours. Consequently, the intravenous administration of the delivery system complexed to a therapeutic DNA encoding TNF led to a rapid and sustained tumour regression over one month (90% complete response, 10% partial response on A431 human epidermoid tumours). It also resulted in tumour suppression for 60% of PC-3 and 50% of DU145 prostate tumours. The treatment was well tolerated by the animals, with no apparent signs of toxicity. Transferrin-bearing polypropylenimine is therefore a highly promising delivery system for cancer therapy

Request more information
Company product page



For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here

Scientific News
Epigenomics of Alzheimer’s Disease Progression
Study of epigenomic modifications reveals immune basis of Alzheimer's disease.
Single-Cell, 42-plexed Protein Analysis Achieved with a New Microchip Technology
A novel microdevice capable of detecting 42 unique immune effector proteins has been developed.
New Therapeutic Strategy Discovered for Ovarian Cancer
New therapeutic target could lead to the first effected targeted therapy for aggressive forms of ovarian cancer.
MAGE Genes Provide Insight into Optimizing Chemotherapy
UT Southwestern Medical Center scientists have identified a new biomarker that could help identify patients who are more likely to respond to certain chemotherapies.
Dynamic Profiling Of The Protein Life Cycle In Response To Pathogens
A quantitative genomic model is used to explain the abundance of proteins in cells based on mRNA expression, translation, and degradation.
New Biomarkers To Spot Pancreatic Cancer Early
A combination of two biomarkers can identify pre-clinical pancreatic cancer.
Two Genetic Mutations That Interact To Lower Heart Attack Risk Identified
About 20 percent of the population has this protective genetic combination.
Epigenetic Signatures that Differentiate Triple-Negative Breast Cancers
Australian researchers have identified epigenetic ‘signatures’ that could help clinicians tell the difference between highly aggressive and more benign forms of triple-negative breast cancer.
A ‘STAR’ is Born: Engineers Devise Genetic 'On' Switch
A new “on” switch to control gene expression has been developed by Cornell scientists.
New Techniques Reveal “Extreme” Gene Copy Range
New findings give scientists the first precise way to study places in the genome where the number of copies of a sequence varies widely from person to person.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters